Assessing the Knowledge and Attitude toward COVID-19 Vaccination in Saudi Arabia
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Population
2.2. Data Collection
2.3. Statistical Analysis
2.4. Ethical Consideration
3. Results
3.1. Sociodemographic Characteristics of Participants
3.2. Knowledge Related to COVID-19 Infection and Vaccine
3.3. Attitudes toward COVID-19 Vaccination
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Hu, B.; Guo, H.; Zhou, P.; Shi, Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021, 19, 141–154. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) [Internet]. Johns Hopkins University. Available online: https://coronavirus.jhu.edu/map.html (accessed on 27 April 2021).
- Daily Report of Coronavirus Disease COVID-19: Ministry of Health MOH. Available online: https://covid19.moh.gov.sa (accessed on 28 April 2021).
- Izda, V.; Jeffries, M.A.; Sawalha, A.H. COVID-19: A review of therapeutic strategies and vaccine candidates. Clin. Immunol. 2021, 222, 108634. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Biswas, N.; Mustapha, T.; Khubchandani, J.; Price, J.H. The Nature and Extent of COVID-19 Vaccination Hesitancy in Healthcare Workers. J. Community Health 2021, 1–8. [Google Scholar] [CrossRef] [Scilit]
- Sallam, M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates. Vaccines 2021, 9, 160. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lazarus, J.V.; Ratzan, S.C.; Palayew, A.; Gostin, L.O.; Larson, H.J.; Rabin, K.; Kimball, S.; El-Mohandes, A. A global survey of potential acceptance of a COVID-19 vaccine. Nat. Med. 2021, 27, 225–228. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Alqudeimat, Y.; Alenezi, D.; AlHajri, B.; Alfouzan, H.; Almokhaizeem, Z.; Altamimi, S.; Almansouri, W.; Alzalzalah, S.; Ziyab, A.H. Acceptance of a COVID-19 Vaccine and Its Related Determinants among the General Adult Population in Kuwait. Med. Princ. Pract. 2021, 30, 262–271. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Alfageeh, E.I.; Alshareef, N.; Angawi, K.; Alhazmi, F.; Chirwa, G.C. Acceptability of a COVID-19 Vaccine among the Saudi Population. Vaccines 2021, 9, 226. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- General Authority for Statistics, Kingdom of Saudi Arabia. 2021. Available online: https://www.stats.gov.sa/en/node (accessed on 25 June 2021).
- Sample Size Calculator. 2021. Available online: http://www.raosoft.com/samplesize.html (accessed on 25 June 2021).
- El-Elimat, T.; AbuAlSamen, M.M.; Almomani, B.A.; Al-Sawalha, N.A.; Alali, F.Q. Acceptance and attitudes toward COVID-19 vaccines: A cross-sectional study from Jordan. PLoS ONE 2021, 16, e0250555. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Almaghaslah, D.; Alsayari, A.; Kandasamy, G.; Vasudevan, R. COVID-19 Vaccine Hesitancy among Young Adults in Saudi Arabia: A Cross-Sectional Web-Based Study. Vaccines 2021, 9, 330. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Mallapaty, S.; Callaway, E. What scientists do and don’t know about the Oxford–AstraZeneca COVID vaccine. Nature 2021, 592, 15–17. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Aleem, A.; Nadeem, A.J. Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT); StatPearls Publishing: Treasure Island, FL, USA, 2021. [Google Scholar]
- Greinacher, A.; Thiele, T.; Warkentin, T.E.; Weisser, K.; Kyrle, P.A.; Eichinger, S. Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N. Engl. J. Med. 2021, 384, 2092–2101. [Google Scholar] [CrossRef] [Scilit]
- Sadoff, J.; Davis, K.; Douoguih, M. Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination—Response from the Manufacturer. N. Engl. J. Med. 2021, 384, 1965–1966. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Scully, M.; Singh, D.; Lown, R.; Poles, A.; Solomon, T.; Levi, M.; Goldblatt, D.; Kotoucek, P.; Thomas, W.; Lester, W. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N. Engl. J. Med. 2021, 384, 2202–2211. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bayas, A.; Menacher, M.; Christ, M.; Behrens, L.; Rank, A.; Naumann, M. Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination. Lancet 2021, 397, e11. [Google Scholar] [CrossRef] [Scilit]
- Graham, F. Daily briefing: European regulator links AstraZeneca vaccine to rare blood clots. Nature 2021. [Google Scholar] [CrossRef] [Scilit]
- Mahase, E. AstraZeneca vaccine: Blood clots are “extremely rare” and benefits outweigh risks, regulators conclude. BMJ 2021, 373, n931. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Mahase, E. COVID-19: AstraZeneca vaccine is not linked to increased risk of blood clots, finds European Medicine Agency. BMJ 2021, 372, n774. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wise, J. COVID-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ 2021, 372, n699. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bosma, N.; Hill, S.; Ionescu-Somers, A.; Kelley, D.; Guerrero, M.; Schott, T. Global Entrepreneurship Monitor 2020/2021 Global Report; Global Entrepreneurship Research Association: London, UK, 2021. [Google Scholar]
- Al-Mohaithef, M.; Padhi, B.K. Determinants of COVID-19 Vaccine Acceptance in Saudi Arabia: A Web-Based National Survey. J. Multidiscip. Healthc. 2020, 13, 1657–1663. [Google Scholar] [CrossRef] [Scilit] [PubMed]
| Vaccinated or Intended to Receive the Vaccine (n = 1267) | Not Intended to Receive the Vaccine (n = 332) | Total (n = 1599) | p | |
|---|---|---|---|---|
| Region of residency | ||||
| Western | 876 (79.6) | 224 (20.4) | 1100 (68.8) | 0.388 |
| Central | 225 (80.4) | 55 (19.6) | 280 (17.5) | |
| Other | 166 (75.8) | 53 (24.2) | 219 (13.7) | |
| Sex 1 | ||||
| Female | 475 (76.5) | 146 (23.5) | 621 (75.8) | 0.019 * |
| Male | 167 (84.3) | 31 (15.7) | 198 (24.2) | |
| Age Group | ||||
| 18–30 years | 418 (76.4) | 129 (23.6) | 547 (34.2) | 0.153 |
| 31–40 years | 415 (79.5) | 107 (20.5) | 522 (32.6) | |
| 41–50 years | 229 (80.9) | 54 (19.1) | 283 (17.7) | |
| >50 years | 205 (83.0) | 42 (17.0) | 247 (15.4) | |
| Nationality | ||||
| Saudi | 1161 (80.2) | 286 (19.8) | 1447 (90.5) | 0.002 * |
| Non-Saudi | 106 (69.7) | 46 (30.3) | 152 (9.50) | |
| Marital Status | ||||
| Single | 419 (80.9) | 99 (19.1) | 518 (32.4) | 0.260 |
| Married | 848 (78.4) | 233 (21.6) | 1081 (67.6) | |
| Education Level | ||||
| ≤High-school | 221 (76.7) | 67 (23.3) | 288 (18.0) | 0.248 |
| University/Postgraduate | 1046 (79.8) | 265 (20.2) | 1311 (82.0) | |
| Employment Status | ||||
| Unemployed | 400 (77.2) | 118 (22.8) | 518 (32.4) | 0.372 |
| Student or employee in the health field | 359 (79.8) | 91 (20.2) | 450 (28.1) | |
| Student or employee in non-related health field | 508 (80.5) | 123 (19.5) | 631 (39.5) | |
| Family Income per Month | ||||
| <SR 4000 | 130 (74.3) | 45 (25.7) | 175 (10.9) | 0.217 |
| SR 4000–10,000 | 403 (79.3) | 105 (20.7) | 508 (31.8) | |
| >SR 10,000 | 734 (80.1) | 182 (19.9) | 916 (57.3) | |
| Vaccinated or Intended to Get the Vaccine (n = 1267) | Not Intended to Get the Vaccine (n = 332) | Total (n = 1599) | p | ||
|---|---|---|---|---|---|
| How dangerous is COVID-19 infection? | |||||
| Not dangerous | 15 (41.7) | 21 (58.3) | 36 (2.30) | <0.001 * | |
| Dangerous | 319 (86.4) | 50 (13.6) | 369 (23.1) | ||
| Varies from person to person | 913 (78.3) | 253 (21.7) | 1166 (72.9) | ||
| I don’t know | 20 (71.4) | 8 (28.6) | 28 (1.80) | ||
| Do you think the vaccine is safe? | |||||
| Yes | 838 (96.5) | 30 (3.50) | 868 (54.3) | <0.001 * | |
| No | 26 (17.9) | 119 (82.1) | 145 (9.10) | ||
| I don’t know | 403 (68.8) | 183 (31.2) | 586 (36.6) | ||
| What is your understanding of the need for a vaccine? | |||||
| Definitely there is a need for a vaccine | 1101 (90.6) | 114 (9.40) | 1215 (76.0) | <0.001 * | |
| No need for a vaccine | 19 (15.8) | 101 (84.2) | 120 (7.50) | ||
| I don’t know | 147 (55.7) | 117 (44.3) | 264 (16.5) | ||
| What is the source of your information? * | |||||
| 1 | Doctors and other healthcare professionals. | 580 (85.4) | 99 (14.6) | 679 (42.5) | <0.001 * |
| 2 | Awareness campaigns. | 597 (91.3) | 57 (8.70) | 654 (40.9) | <0.001 * |
| 3 | Social media. | 598 (80.2) | 248 (19.8) | 746 (46.7) | 0.394 |
| 4 | Friends and family. | 313 (86.2) | 50 (13.8) | 363 (22.7) | <0.001 * |
| 5 | Medical websites. | 392 (78.6) | 107 (21.4) | 499 (31.2) | 0.652 |
| 6 | Other websites. | 47 (56.6) | 36 (43.4) | 83 (5.20) | <0.001 * |
| For Participants Who Are Vaccinated or Intended to Get Vaccinated | |||
|---|---|---|---|
| What drives you to get the vaccine? * | n | % | |
| 1 | Confidence in the decisions of the government of the Kingdom of Saudi Arabia. | 876 | 54.8 |
| 2 | Fear of infection. | 499 | 31.2 |
| 3 | The death of a relative after corona infection. | 106 | 6.60 |
| 4 | My duty to the community to participate in the eradication of the pandemic. | 779 | 48.7 |
| 5 | To be able to travel and practice vaccination related activities. | 505 | 31.6 |
| 6 | Encouragement from the family. | 310 | 19.4 |
| 7 | Other reasons. | 87 | 5.40 |
| For Participants Who Do not Want to Be Vaccinated | |||
| Why you do not want to get vaccinated? * | n | % | |
| 1 | Do not believe in the efficacy of the vaccine. | 68 | 4.30 |
| 2 | Do not believe in the need for the vaccine. | 57 | 3.60 |
| 3 | Got infected with COVID-19 previously and do not need to be vaccinated. | 38 | 2.40 |
| 4 | Do not need the vaccine as I am committed to precautionary measures. | 77 | 4.80 |
| 5 | I think there is a conspiracy about the disease and the vaccine. | 61 | 3.80 |
| 6 | Not eligible for vaccination, due to allergy, pregnancy, other. | 45 | 2.80 |
| 7 | Family opposition. | 10 | 0.60 |
| 8 | Not comfortable with side effects. | 176 | 11.0 |
| 9 | Not confident of the adequacy of previous clinical trials to lunch the vaccine. | 182 | 11.4 |
| 10 | Other reasons. | 40 | 2.50 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zahid, H.M.; Alsayb, M.A. Assessing the Knowledge and Attitude toward COVID-19 Vaccination in Saudi Arabia. Int. J. Environ. Res. Public Health 2021, 18, 8185. https://doi.org/10.3390/ijerph18158185
Zahid HM, Alsayb MA. Assessing the Knowledge and Attitude toward COVID-19 Vaccination in Saudi Arabia. International Journal of Environmental Research and Public Health. 2021; 18(15):8185. https://doi.org/10.3390/ijerph18158185
Chicago/Turabian StyleZahid, Heba M., and May A. Alsayb. 2021. "Assessing the Knowledge and Attitude toward COVID-19 Vaccination in Saudi Arabia" International Journal of Environmental Research and Public Health 18, no. 15: 8185. https://doi.org/10.3390/ijerph18158185
APA StyleZahid, H. M., & Alsayb, M. A. (2021). Assessing the Knowledge and Attitude toward COVID-19 Vaccination in Saudi Arabia. International Journal of Environmental Research and Public Health, 18(15), 8185. https://doi.org/10.3390/ijerph18158185

